ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $219,319 | -95.0% | 6,152 | -93.5% | 0.00% | -100.0% |
| Q2 2023 | $4,379,075 | -9.7% | 94,929 | -21.5% | 0.00% | -20.0% |
| Q1 2023 | $4,847,609 | -63.9% | 120,888 | -58.3% | 0.01% | -66.7% |
| Q4 2022 | $13,435,468 | -31.3% | 289,995 | -38.6% | 0.02% | -34.8% |
| Q3 2022 | $19,560,000 | -8.8% | 472,354 | +31.4% | 0.02% | -8.0% |
| Q2 2022 | $21,449,000 | -39.0% | 359,517 | -25.8% | 0.02% | -24.2% |
| Q1 2022 | $35,173,000 | -23.5% | 484,338 | -11.4% | 0.03% | -13.2% |
| Q4 2021 | $45,963,000 | +7.1% | 546,591 | +14.9% | 0.04% | -2.6% |
| Q3 2021 | $42,904,000 | -43.1% | 475,707 | -39.8% | 0.04% | -40.0% |
| Q2 2021 | $75,355,000 | -14.6% | 790,297 | +1.9% | 0.06% | -24.4% |
| Q1 2021 | $88,283,000 | -13.8% | 775,368 | +4.9% | 0.09% | -6.5% |
| Q4 2020 | $102,367,000 | +189.0% | 739,487 | +71.6% | 0.09% | +155.6% |
| Q3 2020 | $35,415,000 | +34.3% | 430,892 | +27.8% | 0.04% | +16.1% |
| Q2 2020 | $26,373,000 | +49.0% | 337,164 | -15.4% | 0.03% | +10.7% |
| Q1 2020 | $17,705,000 | +31.9% | 398,474 | +26.8% | 0.03% | +86.7% |
| Q4 2019 | $13,418,000 | +66.5% | 314,168 | +66.8% | 0.02% | +50.0% |
| Q3 2019 | $8,059,000 | -5.0% | 188,383 | +41.0% | 0.01% | -9.1% |
| Q2 2019 | $8,484,000 | -15.2% | 133,606 | -7.3% | 0.01% | -15.4% |
| Q1 2019 | $10,000,000 | -28.5% | 144,177 | -55.2% | 0.01% | -31.6% |
| Q4 2018 | $13,993,000 | +3296.4% | 321,834 | +5859.9% | 0.02% | – |
| Q3 2018 | $412,000 | -65.9% | 5,400 | -76.2% | 0.00% | -100.0% |
| Q3 2017 | $1,208,000 | -74.7% | 22,682 | -70.5% | 0.00% | -75.0% |
| Q2 2017 | $4,775,000 | +87.0% | 76,875 | +104.1% | 0.01% | +100.0% |
| Q1 2017 | $2,553,000 | -75.6% | 37,663 | -59.7% | 0.00% | -75.0% |
| Q4 2015 | $10,476,000 | +57.9% | 93,388 | +35.5% | 0.02% | +60.0% |
| Q3 2015 | $6,636,000 | +323.5% | 68,898 | +350.3% | 0.01% | +233.3% |
| Q2 2015 | $1,567,000 | -5.6% | 15,300 | -42.8% | 0.00% | 0.0% |
| Q1 2015 | $1,660,000 | – | 26,728 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |